Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study

P. Siriratnam, P. Sanfilippo, A. van der Walt, S. Sharmin, YC. Foong, WZ. Yeh, C. Zhu, SJ. Khoury, T. Csepany, B. Willekens, M. Etemadifar, S. Ozakbas, P. Nytrova, A. Altintas, A. Al-Asmi, B. Yamout, G. Laureys, F. Patti, M. Simo, A. Surcinelli,...

. 2025 ; 96 (4) : 361-369. [pub] 20250324

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009446
E-zdroje Online Plný text

NLK ProQuest Central od 1944-07-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest) od 1944-07-01 do Před 6 měsíci
Health & Medicine (ProQuest) od 1944-07-01 do Před 6 měsíci
Psychology Database (ProQuest) od 1944-07-01 do Před 6 měsíci

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD. METHODS: This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate. RESULTS: A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, p<0.001) and seronegative NMOSD (HR 0.21, 95% CI 0.08 to 0.51, p<0.001). Longer disease duration (HR 0.97, 95% CI 0.95 to 0.99, p<0.001) and male sex (HR 0.52, 95% CI 0.34 to 0.84, p=0.007) were additional protective variables in reducing the recurrent relapse risk for the AQP4-IgG NMOSD group. CONCLUSION: Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus.

Alfred Health Department of Neurology Melbourne Victoria Australia

American University of Beirut Beirut Lebanon

Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases Istanbul Turkey

Biocruces Bizkaia Health Research Institute Barakaldo Spain

College of Medicine and Health Sciences and Sultan Qaboos University Hospital Sultan Qaboos University Al Khodh Oman

Department of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila Italy

Department of Medicine CORe University of Melbourne Melbourne Victoria Australia

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Czech Republic

Department of Neurology Haydarpasa Numune Training and Research Hospital Istanbul Turkey

Department of Neurology Royal Brisbane Hospital Brisbane Queensland Australia

Department of Neurology Royal Melbourne Hospital Melbourne Victoria Australia

Department of Neurology School of Medicine and Koc University Research Center for Translational Medicine Istanbul Turkey

Department of Neurology Semmelweis University Budapest Hungary

Department of Neurology Universitair Ziekenhuis Gent Gent Belgium

Department of Neurology University of Debrecen Debrecen Hungary

Department of Neuroscience MS Center Neurology Unit S Maria delle Croci Hospital Ravenna Italy

Department of Neuroscience S Maria delle Croci Hospital Ravenna Italy

Department of Neuroscience School of Translational Medicine Monash University Melbourne Victoria Australia

Division of Neurology Department of Medicine Amiri Hospital Kuwait City Kuwait

Faculty of Medicine and Health Sciences Translational Neurosciences Research Group University of Antwerp Wilrijk Belgium

Faculty of Medicine Isfahan University of Medical sciences Isfahan Iran

Hunter Medical Research Institute The University of Newcastle Newcastle New South Wales Australia

Hunter New England Health John Hunter Hospital New Lambton Heights New South Wales Australia

Izmir University of Economics Medical Point Hospital İzmir Turkey

Multiple Sclerosis Research Association Izmir Turkey

Multiple Sclerosis Unit AOU Policlinico G Rodolico San Marco University of Catania Catania Italy

Nehme and Therese Tohme Multiple Sclerosis Center American University of Beirut Medical Center Beirut Lebanon

Neurology Department Harley Street Medical Centre Abu Dhabi UAE

Neurology Dr Etemadifar MS Institute Isfahan Iran

Neurology Galdakao Usanosolo University Hospital Osakidetza Basque Health Service Galdakao Spain

Neurology Royal Hobart Hospital Hobart Tasmania Australia

Neurology Universitair Ziekenhuis Antwerpen Edegem Belgium

Neurology Walton Centre for Neurology and Neurosurgery Liverpool UK

Neuroscience Department of Surgical and Medical Sciences and Advanced Technologies 'G F Ingrassia' University of Catania Catania Italy

The University of Queensland Brisbane Queensland Australia

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009446
003      
CZ-PrNML
005      
20250429135050.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/jnnp-2024-334090 $2 doi
035    __
$a (PubMed)39231582
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Siriratnam, Pakeeran $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Department of Neurology, Melbourne, Victoria, Australia $u Neurology, Walton Centre for Neurology and Neurosurgery, Liverpool, UK $1 https://orcid.org/0000000347512102
245    10
$a Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study / $c P. Siriratnam, P. Sanfilippo, A. van der Walt, S. Sharmin, YC. Foong, WZ. Yeh, C. Zhu, SJ. Khoury, T. Csepany, B. Willekens, M. Etemadifar, S. Ozakbas, P. Nytrova, A. Altintas, A. Al-Asmi, B. Yamout, G. Laureys, F. Patti, M. Simo, A. Surcinelli, M. Foschi, PA. McCombe, R. Alroughani, JL. Sánchez-Menoyo, R. Turkoglu, A. Soysal, J. Lechner Scott, T. Kalincik, H. Butzkueven, V. Jokubaitis, S. Huda, M. Monif, MSBASE study group
520    9_
$a BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD. METHODS: This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate. RESULTS: A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, p<0.001) and seronegative NMOSD (HR 0.21, 95% CI 0.08 to 0.51, p<0.001). Longer disease duration (HR 0.97, 95% CI 0.95 to 0.99, p<0.001) and male sex (HR 0.52, 95% CI 0.34 to 0.84, p=0.007) were additional protective variables in reducing the recurrent relapse risk for the AQP4-IgG NMOSD group. CONCLUSION: Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus.
650    _2
$a lidé $7 D006801
650    12
$a neuromyelitis optica $x imunologie $x farmakoterapie $7 D009471
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a akvaporin 4 $x imunologie $7 D051401
650    12
$a recidiva $7 D012008
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    _2
$a retrospektivní studie $7 D012189
650    12
$a imunoglobulin G $x krev $7 D007074
650    _2
$a autoprotilátky $x krev $7 D001323
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a výsledek terapie $7 D016896
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Sanfilippo, Paul $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Department of Neurology, Melbourne, Victoria, Australia
700    1_
$a van der Walt, Anneke $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Department of Neurology, Melbourne, Victoria, Australia $1 https://orcid.org/0000000242787003
700    1_
$a Sharmin, Sifat $u Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia $1 https://orcid.org/0000000172949723
700    1_
$a Foong, Yi Chao $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $u Neurology, Royal Hobart Hospital, Hobart, Tasmania, Australia
700    1_
$a Yeh, Wei Zhen $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Department of Neurology, Melbourne, Victoria, Australia
700    1_
$a Zhu, Chao $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $1 https://orcid.org/0000000339517501
700    1_
$a Khoury, Samia Joseph $u Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon $u American University of Beirut, Beirut, Lebanon $1 https://orcid.org/0000000331986063
700    1_
$a Csepany, Tunde $u Department of Neurology, University of Debrecen, Debrecen, Hungary
700    1_
$a Willekens, Barbara $u Neurology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium $u Faculty of Medicine and Health Sciences, Translational Neurosciences Research Group, University of Antwerp, Wilrijk, Belgium
700    1_
$a Etemadifar, Masoud $u Faculty of Medicine, Isfahan University of Medical sciences, Isfahan, Iran (the Islamic Republic of) $u Neurology, Dr. Etemadifar MS Institute, Isfahan, Iran (the Islamic Republic of)
700    1_
$a Ozakbas, Serkan $u Izmir University of Economics, Medical Point Hospital, İzmir, Turkey $u Multiple Sclerosis Research Association, Izmir, Turkey
700    1_
$a Nytrova, Petra $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Altintas, Ayse $u Department of Neurology, School of Medicine and Koc University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey
700    1_
$a Al-Asmi, Abdullah $u College of Medicine & Health Sciences and Sultan Qaboos University Hospital, Sultan Qaboos University, Al-Khodh, Oman
700    1_
$a Yamout, Bassem $u Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon $u Neurology Department, Harley Street Medical Centre, Abu Dhabi, UAE
700    1_
$a Laureys, Guy $u Department of Neurology, Universitair Ziekenhuis Gent, Gent, Belgium
700    1_
$a Patti, Francesco $u Neuroscience, Department of Surgical and Medical Sciences and Advanced Technologies 'G.F. Ingrassia', University of Catania, Catania, Italy $u Multiple Sclerosis Unit, AOU Policlinico G Rodolico-San Marco, University of Catania, Catania, Italy
700    1_
$a Simo, Magdolna $u Department of Neurology, Semmelweis University, Budapest, Hungary
700    1_
$a Surcinelli, Andrea $u Department of Neuroscience, S Maria delle Croci Hospital, Ravenna, Italy
700    1_
$a Foschi, Matteo $u Department of Neuroscience, MS Center, Neurology Unit, S. Maria delle Croci Hospital, Ravenna, Italy $u Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy $1 https://orcid.org/0000000203217155
700    1_
$a McCombe, Pamela A $u The University of Queensland, Brisbane, Queensland, Australia $u Department of Neurology, Royal Brisbane Hospital, Brisbane, Queensland, Australia $1 https://orcid.org/0000000327048517
700    1_
$a Alroughani, Raed $u Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait City, Kuwait
700    1_
$a Sánchez-Menoyo, José Luis $u Neurology, Galdakao-Usanosolo University Hospital, Osakidetza-Basque Health Service, Galdakao, Spain $u Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain
700    1_
$a Turkoglu, Recai $u Department of Neurology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
700    1_
$a Soysal, Aysun $u Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey
700    1_
$a Lechner Scott, Jeanette $u Hunter Medical Research Institute, The University of Newcastle, Newcastle, New South Wales, Australia $u Hunter New England Health, John Hunter Hospital, New Lambton Heights, New South Wales, Australia
700    1_
$a Kalincik, Tomas $u Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia $u Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia $1 https://orcid.org/0000000337781376 $7 xx0121848
700    1_
$a Butzkueven, Helmut $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Department of Neurology, Melbourne, Victoria, Australia
700    1_
$a Jokubaitis, Vilija $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia $1 https://orcid.org/0000000239424340
700    1_
$a Huda, Saif $u Neurology, Walton Centre for Neurology and Neurosurgery, Liverpool, UK $1 https://orcid.org/0000000309803750
700    1_
$a Monif, Mastura $u Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia mastura.monif@monash.edu $u Alfred Health, Department of Neurology, Melbourne, Victoria, Australia
710    2_
$a MSBASE study group
773    0_
$w MED00010064 $t Journal of neurology, neurosurgery and psychiatry $x 1468-330X $g Roč. 96, č. 4 (2025), s. 361-369
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39231582 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135045 $b ABA008
999    __
$a ok $b bmc $g 2311060 $s 1246527
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 96 $c 4 $d 361-369 $e 20250324 $i 1468-330X $m Journal of neurology, neurosurgery and psychiatry $n J Neurol Neurosurg Psychiatry $x MED00010064
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...